This application is for continuation of a comprehensive program involving design, synthesis, biological evaluation in vitro and in vivo against human tumor xenografts, murine tumors and selected viruses, biochemical screening and in-depth investigations of mechanism of action and tumor distribution, and pharmacological studies of new anticancer agents of the following classes: analogs of natural and carbocyclic purines, pyrimidines and their nucleosides, antifolates, analogs of the ultimate alkylating agents derivable from cyclophosphamide, ifosfamide and trofosfamide, and chemically-reactive haloethylating agents. New agents will be evaluated for cytotoxicity in vitro against a panel of human solid tumors and leukemias and murine tumors, for biochemical effects against a series of enzymes involved in purine, pyrimidine, and nucleic acid metabolism, and for antiviral activity in vitro. Agents of interest will be evaluated in vivo against selected human tumor xenografts and murine tumors and against selected viruses and also subjected to in-depth biochemical studies on their mechanism of action. Agents determined to be of clinical potential will be evaluated against additional tumor models and viruses and also for pharmacologic disposition and metabolism and their solid tumor distribution characteristics. The results of the biological and biochemical investigations will be used to guide synthesis projects with respect to selection of agents that merit further study and the design of new agents on the basis of observations on structureactivity relationships and mechanisms of action. Specifically, five synthesis-biochemistry projects will provide new agents for biochemical and biological evaluations and investigations; a project on DNA primase will concentrate on this enzyme as a suitable target for cancer chemotherapy; another project will examine distribution of agents in a murine mammary tumor in vivo and correlation with tumor cell kill, and the core components will provide preparative-scale synthesis and analytical services, chemotherapy evaluations in vitro and in vivo, screening against a panel of enzymes involved in nucleic acid metabolism, pharmacologic evaluation, and antiviral evaluation in vitro and in vivo, resulting in a unified and interrelated program of drug development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA034200-10
Application #
3093543
Study Section
Special Emphasis Panel (SRC (I1))
Project Start
1986-04-01
Project End
1995-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
10
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Thottassery, Jaideep V; Sambandam, Vijaya; Allan, Paula W et al. (2014) Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine. Cancer Chemother Pharmacol 74:291-302
Waud, William R; Parker, William B; Gilbert, Karen S et al. (2012) Isolation and characterization of a murine P388 leukemia line resistant to thiarabine. Nucleosides Nucleotides Nucleic Acids 31:14-27
Waud, William R; Gilbert, Karen S; Secrist 3rd, John A (2012) Preclinical antitumor activity of thiarabine in human leukemia and lymphoma xenograft models. Nucleosides Nucleotides Nucleic Acids 31:647-60
Waud, William R; Gilbert, Karen S; Secrist 3rd, John A (2012) Preclinical combination therapy of thiarabine plus various clinical anticancer agents. Nucleosides Nucleotides Nucleic Acids 31:630-46
Waud, William R; Gilbert, Karen S; Secrist 3rd, John A (2011) Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias. Cancer Chemother Pharmacol 68:399-403
Waud, William R; Gilbert, Karen S; Parker, William B et al. (2011) Isolation and characterization of a murine P388 leukemia line resistant to clofarabine. Nucleosides Nucleotides Nucleic Acids 30:826-38
Parker, William B; Shaddix, Sue C; Gilbert, Karen S et al. (2009) Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine. Cancer Chemother Pharmacol 64:253-61
Tiwari, Kamal N; Shortnacy-Fowler, Anita T; Parker, William B et al. (2009) Synthesis and anticancer evaluation of 4'-C-methyl-2'-fluoro arabino nucleosides. Nucleosides Nucleotides Nucleic Acids 28:657-77
Someya, Hitoshi; Waud, William R; Parker, William B (2006) Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine. Cancer Chemother Pharmacol 57:772-80
Thottassery, Jaideep V; Westbrook, Louise; Someya, Hitoshi et al. (2006) c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther 5:400-10

Showing the most recent 10 out of 80 publications